3-氟苯甲酰肼 | 499-55-8

• 物质功能分类: 化学试剂 - 有机试剂 - 肼
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氟苯甲酰肼
• 中文别名: 3-氟苯酰肼
• 英文名称: 3-fluoro-benzoic acid hydrazide
• 英文别名: 3-fluorobenzohydrazide；3-fluorobenzoyl hydrazine；3-fluorobenzhydrazide；3-fluorobenzoic hydrazide
• CAS: 499-55-8
• 化学式: C₇H₇FN₂O
• mdl: MFCD00060561
• 分子量: 154.144
• InChiKey: UUISEXNUHLZEDB-UHFFFAOYSA-N

物化性质

• 熔点：
  139-143 °C (lit.)
• 密度：
  1.272±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  按规格使用和贮存，不会发生分解，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36,S36/37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2928000090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封保存，并置于通风、干燥的环境里。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Fluorobenzhydrazide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Fluorobenzhydrazide
CAS number: 499-55-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H7FN2O
Molecular weight: 154.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

合成制备方法

暂无相关描述。

用途

暂无相关信息。

反应信息

• 作为反应物：
  描述：

  3-氟苯甲酰肼 以 乙腈 为溶剂， 反应 24.17h， 生成 4-[(3-fluorobenzoyl)hydrazonomethylamino]-2-hydroxybenzoic acid
  参考文献：
  名称：

  New fluorine-containing hydrazones active against MDR-tuberculosis

  摘要：

  Several new fluorine-containing hydrazones were synthesized and screened for their in vitro anti-mycobacterial activity. Nine of these derivatives have shown a remarkable activity against MDR-TB strain with MIC 0.5 mu g/mL and high value of selectivity index (SI). Compound 3h with the highest SI (1268.58) was used for stability evaluation with putative metabolites (ciprofloxacin and formylciprofloxacin) detection. Compound 3h was stable at pH 7.4 of aqueous buffer and rat plasma, in acidic buffers (at pH 3 and 5) slow decomposition was observed. Interestingly, no formylciprofloxacin was detected in the solution, and only slightly increased concentration of ciprofloxacin was observed instead. Trifluoromethyl hydrazones 3f and 3g exhibited the best activity also against two strains of Mycobacterium kansasii (MIC 1-4 mu mol/L). All evaluated compounds were found to be non-cytotoxic. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.07.052
• 作为产物：
  描述：

  间氟苯甲酸 在 硫酸 、 一水合肼 作用下， 以 neat (no solvent) 为溶剂， 生成 3-氟苯甲酰肼
  参考文献：
  名称：

  1,2,4-三唑-3-硫酮化合物作为二嗪金属β-内酰胺酶的抑制剂。

  摘要：

  金属β-内酰胺酶（MBLs）引起革兰氏阴性细菌对β-内酰胺类抗生素的耐药性并引起人们的严重关注，因为它们可以使最后的碳青霉烯类药物失活，并且仍然缺乏具有临床价值的MBL抑制剂。我们之前确定了在其二嗪活性位点内4-氨基-2,4-二氢-5-（2-甲基苯基）-3H-1,2,4-三唑-3-硫酮（化合物IIIA）的原始结合模式。 L1 MBL。在这里，我们提出了L1与相应的非氨基化合物IIIB（1,2-二氢-5-（2-甲基苯基）-3H-1,2,4-三唑-3-硫酮）的配合物的晶体结构。出乎意料的是，IIIB的结合模式与IIIA相似，但相反。3D结构表明三唑-硫酮骨架适合结合二锌金属酶的催化位点。根据这些结果，我们合成了IIIA或IIIB的54个类似物。有19个显示的IC50值在微摩尔范围内，朝着五个代表性MBL（即L1，VIM-4，VIM-2，NDM-1和IMP-1）中的至少一个显示。其中五个对至少四

  DOI：

  10.1002/cmdc.201700186

文献信息

• [EN] TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS PHÉNYLE TRIAZOLE EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2018093579A1

  公开（公告）日：2018-05-24

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用盐，上述任何一个的立体异构体，或它们的混合物是APJ受体的激动剂，可能用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构：(I)，(II)，其中变量的定义在此提供。
• Synthesis of novel 5-(aroylhydrazinocarbonyl)escitalopram as cholinesterase inhibitors
  作者：Mehr-un Nisa、Munawar A. Munawar、Amber Iqbal、Asrar Ahmed、Muhammad Ashraf、Qurra-tul-Ann A. Gardener、Misbahul A. Khan

  DOI：10.1016/j.ejmech.2017.06.036

  日期：2017.9

  A novel series of 5-(aroylhydrazinocarbonyl)escitalopram (58–84) have been designed, synthesized and tested for their inhibitory potential against cholinesterases. 3-Chlorobenzoyl- (71) was found to be the most potent compound of this series having IC50 1.80 ± 0.11 μM for acetylcholinesterase (AChE) inhibition. For the butyrylcholinesterase (BChE) inhibition, 2-bromobenzoyl- (76) was the most active

  已经设计，合成和测试了一系列新型的5-（芳酰基肼基羰基）依他普仑（58-84）对胆碱酯酶的抑制潜力。发现3-氯苯甲酰基- （71）是该系列中最有效的化合物，对乙酰胆碱酯酶（AChE）的抑制作用的IC 50为1.80±0.11μM。对于丁酰胆碱酯酶（BChE）抑制，2-溴苯甲酰基-（76）是该系列中活性最高的化合物，IC 50为2.11±0.31μM。构效关系说明温和的给电子基团增强了酶的抑制作用，而吸电子基团降低了除o -NO 2以外的抑制。然而，取代基的大小和位置影响酶抑制。。在AChE的对接研究中，配体71、72和76分别显示5874、5756和5666以及ACE的得分分别为-64.92，-203.25和-140.29 kcal / mol。在BChE的情况下，配体71、76和81分别显示出ACE值为-170.91，-256.84和-235.97 kcal / mol的高分6016、6150和5994。
• Synthesis, spectroscopic and radical scavenging studies of palladium(II)-hydrazide complexes
  作者：Qurrat Ul Ain、Uzma Ashiq、Rifat Ara Jamal、Mohammad Mahrooof-Tahir

  DOI：10.1016/j.saa.2013.05.064

  日期：2013.11

  In present study, a series of palladium(II) complexes with biologically active hydrazide ligands have been synthesized, characterized and screened for their antioxidant (superoxide and DPPH radical scavenging) properties. Spectral studies (FT-IR, EI-mass, 13C and 1H NMR spectroscopy) and physico-chemical measurements including elemental analysis, magnetic susceptibility and conductivity measurements

  在本研究中，已经合成了一系列具有生物活性酰肼配体的钯（II）配合物，对其特性进行了表征并筛选了其抗氧化（超氧化物和DPPH自由基清除）性能。光谱研究（FT-IR，EI质谱，13 C和1 H NMR光谱）和包括元素分析，磁化率和电导率测量在内的物理化学测量均代表了所有配合物的方形平面结构。取代和未取代benzohydrazides（1 - 4）已经显示单齿行为形成通式的配合物[PDL 2氯2 ]。但是，吡啶碳酰肼（5和6）以[PdLCl 2 ]通式的二齿形式配位，产生稳定的五元螯合环。与游离酰肼相比，发现所有钯配合物都是更有效的DPPH自由基抑制剂。与标准抗氧化剂没食子酸丙酯丙酯相比，这些配合物甚至是更强的DPPH清除剂。与无活性的游离酰肼相比，该络合物还显示出良好的超氧化物清除能力，但是与标准的超氧化物抑制剂抗坏血酸相比，该络合物是较弱的超氧化物清除剂。评估了一个有趣的结构活动关系。
• [EN] HEPARANASE INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS D'HÉPARANASE ET LEUR UTILISATION
  申请人：BETA THERAPEUTICS PTY LTD

  公开号：WO2018107200A1

  公开（公告）日：2018-06-21

  The invention relates to functionalized quinazoline compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as heparanase inhibitors for the treatment of diseases or conditions related to heparanse activity.

  本发明涉及功能化喹唑啉化合物，包括此类化合物的药物组合物，以及此类化合物作为肝素酶抑制剂用于治疗与肝素酶活性相关的疾病或状况的使用。
• [EN] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES<br/>[FR] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES
  申请人：BAYER AG

  公开号：WO2021028382A1

  公开（公告）日：2021-02-18

  The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式（I）中R1、R2、R3、R4、R5、R6、R7和R8如所定义的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是癌症或与异常AHR信号传导相关的疾病，或与失调免疫反应或其他与异常AHR信号传导相关的疾病有关的情况，作为唯一药剂或与其他活性成分组合使用。

表征谱图